ライフサイエンスコーパス: total parenteral nutrition

1 eterm infants who are typically supported by total parenteral nutrition.

2 ation predicts the duration of dependence on total parenteral nutrition.

3 who were provided nutritional support using total parenteral nutrition.

4 transpyloric feeding tubes, and 7% received total parenteral nutrition.

5 ng bone marrow transplantation and receiving total parenteral nutrition.

6 tion included short-bowel syndrome requiring total parenteral nutrition.

7 ilure who experience severe complications on total parenteral nutrition.

8 y, evidence of bowel obstruction, and use of total parenteral nutrition.

9 ction, malabsorption and the requirement for total parenteral nutrition.

10 tically ill neonates, and patients receiving total parenteral nutrition.

11 ged conservatively with dietary measures and total parenteral nutrition.

12 mia during intensive insulin therapy than is total parenteral nutrition.

13 ne dose typically administered with standard total parenteral nutrition.

14 ial barrier function that is associated with total parenteral nutrition.

15 icantly increased with the administration of total parenteral nutrition.

16 antly lower than in wild-type mice receiving total parenteral nutrition.

17 t-bowel syndrome, which required him to have total parenteral nutrition.

18 surviving graft recipients are weaned off of total parenteral nutrition.

19 asis remain complex problems for patients on total parenteral nutrition.

20 with (odds ratio [95% confidence interval]): total parenteral nutrition (2.79 [1.26-6.17]), dialysis

21 (3.9% vs 17.5%, RR: 0.2, CI: 0.09-0.5), and total parenteral nutrition (3.9% vs 22.5%, RR: 0.2, CI:

22 .9% vs 17.5%; RR, 0.2 [95% CI, .09-.5]), and total parenteral nutrition (3.9% vs 22.5%; RR, 0.2 [95%

23 9418], P<0.001), and the incidence of use of total parenteral nutrition (31 percent vs. 55 percent, P

24 nical ventilation (67.0% vs 44.1%), received total parenteral nutrition (63.6% vs 45.1%), and were on

25 dence interval, 1.8 to 148.1) and receipt of total parenteral nutrition (adjusted odds ratio, 9.2; 95

26 Total parenteral nutrition administration was associated

27 ion, alcohol use, use of medications, recent total parenteral nutrition, age at symptom onset, recent

28 Seven days of total parenteral nutrition alone enhanced plasma GSH lev

29 studies indicate that copper requirements in total parenteral nutrition amount to 0.3 mg/day in the a

30 Presence of total parenteral nutrition and Candida albicans was asso

31 o distinct physiological differences between total parenteral nutrition and enteral nutrition that ar

32 de malabsorptive disorders, gastric surgery, total parenteral nutrition and excessive zinc intake.

33 thers do not, and why some patients tolerate total parenteral nutrition and others develop liver dysf

34 Avoiding total parenteral nutrition and prophylactic antibiotics,

35 All required total parenteral nutrition and repeated albumin infusion

36 ediate care unit, chronic care requirements (total parenteral nutrition and tracheostomy), specific d

37 l of villus atrophy by the administration of total parenteral nutrition, and a model of villus hypert

38 Nonimmune animals were randomized to chow or total parenteral nutrition, and after 5 days of diet wer

39 ain triglycerides, therapeutic paracentesis, total parenteral nutrition, and somatostatins.

40 Sepsis and total parenteral nutrition-associated cholestasis remain

41 ytosterols in parenteral lipid solutions and total parenteral nutrition-associated cholestasis.

42 hionine are the most promising treatments of total parenteral nutrition-associated cholestasis.

43 tohepatitis, primary sclerosing cholangitis, total parenteral nutrition-associated liver disease, and

44 Patients with short-gut syndrome may develop total parenteral nutrition-associated liver disease, whi

45 All surviving patients weaned-off total parenteral nutrition at a median time of 32 days a

46 d glucose into the systemic circulation with total parenteral nutrition at rates that approximate usu

47 Repeat sepsis on total parenteral nutrition before transplant (hazard rat

48 e premature infants, patients with long-term total parenteral nutrition, Crohn's disease, cystic fibr

49 art disease (HR 3.70; 95% CI 1.97-6.95), and total parenteral nutrition dependence (HR 4.02; 95% CI 2

50 A total of 500 patients with total parenteral nutrition-dependent catastrophic and ch

51 lbumin to hypoalbuminemic patients receiving total parenteral nutrition does not improve morbidity or

52 tter define the parameters that best predict total parenteral nutrition failure and the unique mechan

53 isease complicated by short gut syndrome and total parenteral nutrition failure.

54 following an active infection, seven of nine total parenteral nutrition-fed animals continued to have

55 ore than or equal to 13, expected to require total parenteral nutrition for at least 5 days.

56 ept for a recipient of CLDILTx, currently on total parenteral nutrition for late fistula.

57 by carbachol and glucose were higher in the total parenteral nutrition group compared with the contr

58 Ion transport in the total parenteral nutrition group was significantly incre

59 Total parenteral nutrition has significant effects on in

60 atio, 5.8 [95% CI, 3.0 to 11.3]), receipt of total parenteral nutrition (hazard ratio, 4.1 [CI, 2.3 t

61 intra-abdominal abscess in 23 patients, and total parenteral nutrition in 74 (36%).

62 Our understanding of the effects of total parenteral nutrition in critical illness has been

63 osing cholangitis, cholestasis of pregnancy, total parenteral nutrition-induced cholestasis, and drug

64 o assess the role of interferon-gamma on the total parenteral nutrition-induced loss of epithelial ba

65 ple, we addressed critical care therapy use (total parenteral nutrition, invasive mechanical ventilat

66 y injured patients compared with intravenous total parenteral nutrition (IV TPN) or no nutritional su

67 Total parenteral nutrition led to a loss of EBF, and thi

68 Investigations suggest that total parenteral nutrition may compromise bactericidal a

69 al permeability in interferon-gamma knockout total parenteral nutrition mice was significantly lower

70 Although there is evidence to suggest that total parenteral nutrition more effectively spares prote

71 These factors may make total parenteral nutrition more efficacious, at least in

72 reased dependence on enteral tube feeding or total parenteral nutrition [odds ratio (OR) 4.30, 95% co

73 rition: odds ratio, 2.65; 95% CI, 1.93-3.63; total parenteral nutrition: odds ratio, 3.27; 95% CI, 2.

74 To investigate the effect of total parenteral nutrition on intestinal ion transport,

75 Wild-type mice received total parenteral nutrition or enteral diet (control grou

76 ointestinal complications (P = 0.03), use of total parenteral nutrition (P < 0.001), and lung transpl

77 or/current hepatitis C diagnosis (P = .044), total parenteral nutrition (P = .0028), complicated diab

78 The use of total parenteral nutrition (p = 0.03), longer duration o

79 Seven were put on total parenteral nutrition plus octreotide.

80 Total parenteral nutrition (PN), including fat administe

81 Patients received total parenteral nutrition prepared either with a lipid

82 en are noted with stones in association with total parenteral nutrition, prolonged fasting, or ileal

83 comparable with patients given conventional total parenteral nutrition regimens, even when criticall

84 derwent multivisceral transplantation due to total parenteral nutrition-related liver disease.

85 oped computing anatomy of reconstructed gut, total parenteral nutrition requirements, cause of GF, an

86 Total parenteral nutrition should be considered only in

87 Total parenteral nutrition significantly increased small

88 de shortage of injectable zinc available for total parenteral nutrition supplementation over the last

89 Total parenteral nutrition support of sham animals follo

90 uding much higher serum insulin responses to total parenteral nutrition than with enteral nutrition t

91 400 IU of vitamin D(3) and was dependent on total parenteral nutrition that contained 200 IU of vita

92 Enteral nutrient deprivation via total parenteral nutrition (TPN) administration leads to

93 Lipid emulsions are a key component of total parenteral nutrition (TPN) and are administered to

94 d male rats (approximately 235 g) were given total parenteral nutrition (TPN) and treated with recomb

95 ntrations in hospitalized patients beginning total parenteral nutrition (TPN) and whether a 3-d regim

96 erative length of stay, ventilator days, and total parenteral nutrition (TPN) days.

97 medium-chain triacylglycerols (MCTs) during total parenteral nutrition (TPN) enhanced macrophage res

98 Then the animals were maintained on total parenteral nutrition (TPN) for 10 days, after whic

99 40% to 60% of infants who require long-term total parenteral nutrition (TPN) for intestinal failure

100 cadaver donors have become an alternative to total parenteral nutrition (TPN) for the treatment of ir

101 Prior research has shown that mice fed total parenteral nutrition (TPN) have reduced GALT T and

102 Total parenteral nutrition (TPN) is a life-saving treatm

103 Total parenteral nutrition (TPN) is an invasive and adva

104 Total parenteral nutrition (TPN) is commonly used clinic

105 Total parenteral nutrition (TPN) leads a loss of epithel

106 showed that enteral nutrient deprivation or total parenteral nutrition (TPN) led to a loss of intest

107 t bowel syndrome are maintained on long-term total parenteral nutrition (TPN) or more frequently cons

108 G), dialysis for acute kidney failure (AKF), total parenteral nutrition (TPN) or tracheostomy.

109 Both intravenous and intragastric total parenteral nutrition (TPN) produce GALT atrophy, b

110 e lipid emulsions in modern formulations for total parenteral nutrition (TPN) provide essential fatty

111 cine tracer technique after 24 h of a stable total parenteral nutrition (TPN) regimen.

112 ich involved removal of amino acids from the total parenteral nutrition (TPN) solution for 8 h before

113 Prior work shows that mice fed total parenteral nutrition (TPN) solutions either intrav

114 ed to receive for > or = 5 d tube feeding or total parenteral nutrition (TPN) that had identical ener

115 aper we show that feeding chemically defined total parenteral nutrition (TPN) to genetically normal,

116 birth weight (VLBW) infants are dependent on total parenteral nutrition (TPN) to prevent hypoglycemia

117 e enteroplasty [STEP]) in terms of survival, total parenteral nutrition (TPN) weaning, and complicati

118 nit and receiving mechanical ventilation and total parenteral nutrition (TPN) were measured for > or

119 Patients received total parenteral nutrition (TPN) with caloric intake 20%

120 nts were females with a history of long-term total parenteral nutrition (TPN) with TPN-related choles

121 jejunal early enteral nutrition (NJEEN) with total parenteral nutrition (TPN), after pancreaticoduode

122 essional interest, with special reference to total parenteral nutrition (TPN), an area in which I hav

123 occurrence of significant infection, days of total parenteral nutrition (TPN), and days of injectable

124 ics and antifungals, and ICU factors such as total parenteral nutrition (TPN), blood product transfus

125 In several models, including rats given total parenteral nutrition (TPN), IGF-I more potently st

126 on of antibiotic administration, duration of Total Parenteral Nutrition (TPN), mother age, birth orde

127 We utilized a model of total parenteral nutrition (TPN), or enteral nutrient de

128 a model of enteral nutrient deprivation, or total parenteral nutrition (TPN), resulting in intestina

129 Mice that received total parenteral nutrition (TPN), which deprives the ani

130 inal failure patients do well with long-term total parenteral nutrition (TPN), while others develop l

131 Total parenteral nutrition (TPN), with the complete remo

132 He recovered from PTLD but developed total parenteral nutrition (TPN)-induced liver failure.

133 liver disease (one), A-1-A deficiency (one), Total Parenteral Nutrition (TPN)-related (one), cryptoge

134 ied in a model of mucosal atrophy induced by total parenteral nutrition (TPN).

135 opment of gut failure (GF) with the need for total parenteral nutrition (TPN).

136 ctly into the veins of rats by the method of total parenteral nutrition (TPN).

137 nal inflammation are common complications of total parenteral nutrition (TPN).

138 thyroid gland function in patients receiving total parenteral nutrition (TPN).

139 port was provided to rats for 7 days by oral total parenteral nutrition (TPN; elemental diet) 307 kca

140 , and judicious jejunostomy tube feeding, or total parenteral nutrition usage may reduce morbidity.

141 oplasms, bone marrow/organ transplantations, total parenteral nutrition, vaccinations, oral contracep

142 3.8 years, and time from ITx to cessation of total parenteral nutrition was 31 days.

143 Total parenteral nutrition was discontinued 1 week postt

144 The percentages of infants who depended on total parenteral nutrition were 17 of 36 (47.2 percent)

145 , tumor size larger than 10 cm, and need for total parenteral nutrition were shown to further define

146 standard therapy for short bowel syndrome is total parenteral nutrition, which is expensive and assoc

147 Patients received total parenteral nutrition with standard (1.5 g . kg(-1)